{"url":"https://whatshealthyandwhy.com/naringenin/anti-inflammatory-and-metabolic-health","path":"/naringenin/anti-inflammatory-and-metabolic-health","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/naringenin/anti-inflammatory-and-metabolic-health.json","markdown":"https://whatshealthyandwhy.com/naringenin/anti-inflammatory-and-metabolic-health.md"},"topic":{"slug":"naringenin","name":"Naringenin","url":"https://whatshealthyandwhy.com/naringenin"},"slug":"anti-inflammatory-and-metabolic-health","order":1,"title":"Anti-Inflammatory, Metabolic, and Cardiovascular Effects","question":"Does naringenin from grapefruit lower cholesterol and inflammation?","answer":"Naringenin may lower cholesterol and inflammation, but evidence is mostly from animal studies, with few small human trials using mixed citrus products.","description":"How this citrus flavonoid found in grapefruit and oranges reduces inflammation, improves lipid profiles, and protects against metabolic syndrome","confidence":2,"confidenceNote":"Rodent and cell data are consistent; human trials are few, often under 50 people, and mostly used grapefruit juice or bergamot rather than isolated naringenin.","evidenceSummary":{"metaAnalysisCount":0,"newestStudyYear":2025},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Herbs & Spices","subcategorySlug":"herbs","url":"https://whatshealthyandwhy.com/explore/good-for-you/herbs"},"actions":["Eat citrus regularly: grapefruit is the richest source (about 40–70 mg naringenin/naringin each), then oranges and tangerines.","Check for grapefruit–drug interactions before eating grapefruit daily or taking high-dose supplements; occasional grapefruit is generally fine.","If you consider a supplement, ask your doctor first: capsules are typically 250–500 mg, and trials mostly used bergamot extract or grapefruit juice [1]."],"cautions":["Naringenin and naringin inhibit CYP3A4 and CYP1A2 liver enzymes, affecting certain statins, calcium channel blockers, immunosuppressants and anticoagulants; check with your pharmacist or doctor.","Lipid effects were less consistent in obesity and diabetes models, so do not replace prescribed cholesterol or diabetes treatment [4]."],"simpleText":"Naringenin is the principal flavonoid in grapefruit — the compound responsible for its characteristic bitter edge — and is also found in oranges, tangerines, tomatoes, and cherries. It belongs to the flavanone subclass of polyphenols and has been studied for its ability to quiet inflammation through NF-κB suppression, activate the body's antioxidant defenses via Nrf2, lower LDL cholesterol and triglycerides, improve insulin sensitivity, and protect blood vessels from atherosclerotic damage [1][2][3]. Most of the robust evidence comes from preclinical and animal studies, with emerging clinical data in people with hypercholesterolemia and metabolic syndrome. People taking certain medications should be aware of grapefruit's well-known interaction with liver enzymes before regularly consuming large quantities.","mediumText":"How Naringenin Works\n\nNaringenin belongs to the flavanone subclass of flavonoids — structurally distinct from flavonols like quercetin and kaempferol by the absence of a double bond in the C ring, which gives it a slightly different receptor-binding profile. Despite this structural distinction, naringenin engages many of the same core signaling pathways as other well-studied flavonoids, while also activating metabolic pathways of particular relevance to lipid regulation and insulin signaling.\n\nAnti-Inflammatory Mechanisms: NF-κB and Nrf2\n\nNaringenin inhibits NF-κB (nuclear factor kappa B), the transcription factor that functions as a master switch for pro-inflammatory gene expression. By blocking IκB kinase (IKK) and preventing IκB-α degradation, naringenin keeps NF-κB sequestered in the cytoplasm and unable to drive production of TNF-α, IL-1β, IL-6, and COX-2 [5]. It also downregulates Th1 cytokines — the inflammatory signaling molecules that drive autoimmune-type activation — and inhibits xanthine oxidase, an enzyme that generates reactive oxygen species as a byproduct of uric acid metabolism.\n\nSimultaneously, naringenin activates Nrf2, the transcription factor that induces the cell's own antioxidant enzymes: superoxide dismutase (SOD), catalase, glutathione peroxidase, and glutathione S-transferase [5]. This dual action — suppressing inflammatory signals while boosting endogenous antioxidant capacity — is a pattern shared with other plant polyphenols and likely explains the consistency of effect across diverse tissue models.\n\nMetabolic Regulation: AMPK and PPARα\n\nWhat distinguishes naringenin from many other flavonoids is its pronounced activity on metabolic signaling pathways. Naringenin activates AMPK (AMP-activated protein kinase), often called the cellular energy sensor, which responds to low energy states by shifting metabolism toward fat burning and away from fat storage. AMPK activation inhibits fatty acid synthesis (by phosphorylating and inactivating acetyl-CoA carboxylase) and promotes fatty acid oxidation in the liver [3].\n\nNaringenin also activates PPARα (peroxisome proliferator-activated receptor alpha), a nuclear receptor that controls genes involved in fat transport, beta-oxidation, and ketone body production. PPARα activation in the liver reduces hepatic triglyceride accumulation, decreases VLDL production, and lowers circulating triglycerides. Together, AMPK and PPARα activation explain why naringenin shows consistent lipid-lowering effects across animal studies [3].\n\nLipid Metabolism: Multiple Mechanisms\n\nThe 2022 update by Yang and colleagues identified several distinct mechanisms by which naringenin (and its glycoside naringin) improve lipid profiles [4]:\n\n- LDL clearance: Naringenin suppresses PCSK9, the protein that degrades LDL receptors on liver cells. Lower PCSK9 means more LDL receptors stay active and remove more LDL-cholesterol from circulation — the same principle exploited by the newest class of cholesterol-lowering drugs.\n- Bile acid conversion: It promotes conversion of hepatic cholesterol to bile acids, reducing intracellular cholesterol load.\n- Dietary fat absorption: Naringin inhibits pancreatic lipase, the enzyme that breaks down dietary triglycerides in the small intestine, modestly reducing fat absorption from meals.\n- Hepatic steatosis prevention: By promoting fat oxidation and inhibiting fat synthesis simultaneously, naringenin protects against non-alcoholic fatty liver disease in animal models.\n\nCardiovascular Protection\n\nNaringenin protects blood vessels through multiple mechanisms that overlap with its anti-inflammatory and metabolic effects. In endothelial cells, it preserves nitric oxide synthase (eNOS) function, maintaining healthy vasodilation and reducing the expression of adhesion molecules (VCAM-1, ICAM-1) that recruit immune cells to vessel walls — the first step in atherosclerotic plaque formation [2]. It reduces oxidized LDL-induced endothelial damage and inhibits foam cell formation, the process by which macrophages loaded with oxidized cholesterol accumulate in artery walls.\n\nThe review by Moghaddam and colleagues documented protective effects across several cardiovascular conditions including diabetic cardiomyopathy, ischemia-reperfusion injury, and diet-induced atherosclerosis, consistently through antioxidant and anti-inflammatory mechanisms [2].\n\nFood Sources and Concentrations\n\nNaringenin content in food is most concentrated in citrus:\n\n- Grapefruit — the richest source; naringenin accounts for the bitter taste. Both flesh and juice contain meaningful amounts, with one grapefruit providing roughly 40–70 mg of naringenin/naringin combined.\n- Oranges and tangerines — lower concentrations than grapefruit but still significant contributors for regular consumers\n- Tomatoes — naringenin is present in tomato skin at modest concentrations\n- Cherries — present at lower levels\n- Bergamot — a citrus fruit used in supplements and Earl Grey tea; particularly high in flavanones including naringenin derivatives\n\nCooking and processing affect content variably. Grapefruit juice retains naringenin well. Fermentation (as in kvass or some fermented citrus preparations) increases bioavailability by breaking glycoside bonds.\n\nSupplementation\n\nConcentrated naringenin supplements are available, typically 250–500 mg per capsule, as isolated naringenin or as bergamot extract, which is a flavanone-rich citrus derivative studied specifically in clinical trials for lipid lowering. Clinical studies that have demonstrated effects used doses in the 600–800 μM/day range, primarily in individuals with hypercholesterolemia [1].\n\nDrug interaction note: Naringenin and its glycoside naringin inhibit CYP3A4 and CYP1A2 — cytochrome P450 liver enzymes responsible for metabolizing a wide range of medications. This is the well-known grapefruit-drug interaction. Affected medications include certain statins, calcium channel blockers, immunosuppressants, anticoagulants, and many others. Anyone taking medications should check for grapefruit interactions before adding high-dose naringenin supplements or consuming large quantities of grapefruit regularly. Occasional grapefruit consumption is generally fine; consistent daily intake of grapefruit or high-dose supplements is where interactions become clinically significant.\n\nSee our quercetin page for a related flavonoid with strong anti-inflammatory evidence and a well-developed clinical base. The hesperidin page covers another citrus flavanone with particularly strong venous circulation evidence. The bergamot page addresses the most clinically studied citrus flavanone preparation for lipid lowering.","deepText":"Evidence Review\n\nClinical Evidence: Promising but Limited\n\nThe most clinically relevant synthesis is the 2019 review by Salehi and colleagues (PMID 30634637), published in Pharmaceuticals (Basel), which catalogued human clinical trials involving naringenin and naringin. The review identified that most human data involves cardiovascular endpoints in compromised populations — specifically individuals with hypercholesterolemia and overweight — rather than healthy volunteers. Doses in human trials ranged from approximately 600 to 800 μM/day.\n\nKey clinical findings documented in the review include arterial stiffness improvements following grapefruit juice consumption (containing naringenin glycoside) in postmenopausal women, alongside favorable changes in inflammatory markers in small trials. The reviewers concluded that naringenin's ability to improve endothelial function \"has been well-established,\" but emphasized that pharmacokinetic characterization in humans remains incomplete and that larger, controlled trials are needed to establish dose-response relationships and clinical efficacy thresholds.\n\nLimitation: The clinical trial literature on naringenin specifically (as opposed to grapefruit juice, naringin, or bergamot extract) is sparse. Most human data uses mixed citrus preparations rather than isolated naringenin, making it difficult to attribute effects exclusively to this compound. Effect sizes in existing trials are generally modest and many studies are small (under 50 participants).\n\nCardiovascular Effects: Preclinical Evidence Base\n\nMoghaddam and colleagues (PMID 32910944), published in European Journal of Pharmacology in 2020, conducted a detailed preclinical review of naringenin and naringin's cardiovascular effects across animal and cell-culture models. The review organized evidence by mechanism and condition type:\n\nAntioxidant activity: Across multiple oxidative stress models, naringenin consistently enhanced activity of endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase) and reduced malondialdehyde (MDA), a marker of lipid peroxidation. Effect sizes in rodent models were substantial — 40–60% reductions in oxidative markers at relevant doses.\n\nAnti-inflammatory activity: Naringenin reduced circulating TNF-α, IL-6, and IL-1β in models of diet-induced cardiovascular disease. The anti-inflammatory effects were particularly pronounced in models of diabetic cardiomyopathy, where chronic low-grade inflammation drives cardiac fibrosis and dysfunction.\n\nIschemia-reperfusion protection: In models of cardiac ischemia (blocked blood flow followed by reperfusion), naringenin pretreatment reduced infarct size and preserved cardiac function by limiting oxidative burst during reperfusion and reducing cardiomyocyte apoptosis.\n\nLimitation: All primary studies in this review are animal or cell-culture models. The cardiovascular protection in ischemia models, while mechanistically compelling, has not been tested in human trials. Translation from rodent cardiac physiology to human outcomes is uncertain.\n\nMetabolic Syndrome: AMPK and PPARα Mechanisms\n\nMassaro and colleagues (PMID 36043734), published in Endocrine, Metabolic and Immune Disorders - Drug Targets in 2023, examined the mechanistic basis of naringenin's effects on components of metabolic syndrome — a cluster of conditions including abdominal obesity, elevated triglycerides, low HDL, high blood pressure, and impaired fasting glucose.\n\nThe review documented that naringenin and naringin consistently improved multiple metabolic syndrome parameters in animal models:\n\n- Obesity: Reduced body weight gain and visceral fat accumulation through AMPK activation, which shifts energy metabolism toward fatty acid oxidation\n- Dyslipidemia: Reduced total cholesterol, LDL, and triglycerides by 20–40% in hyperlipidemic animal models; increased HDL in most studies\n- Insulin resistance: Improved insulin signaling through IRS-1/PI3K/Akt pathway upregulation and reduced hepatic gluconeogenesis\n- Hepatic steatosis: Prevented accumulation of liver triglycerides through combined PPARα activation (increasing fat oxidation) and SREPB-1c suppression (decreasing fat synthesis)\n\nThe authors noted that while the preclinical evidence is mechanistically well-supported, clinical application has been limited by bioavailability challenges and the absence of adequately powered human trials. They identified AMPK and PPARα as the most pharmacologically tractable targets for clinical translation.\n\nLipid Metabolism: PCSK9, Bile Acids, and Absorption\n\nYang and colleagues (PMID 35189328), published in the Journal of Nutritional Biochemistry in 2022, provided the most mechanistically detailed account of how citrus flavanones affect lipid metabolism. The review highlighted PCSK9 suppression as a particularly important mechanism: PCSK9 is a protein that marks LDL receptors for degradation, reducing the liver's capacity to clear LDL from blood. Naringenin's suppression of PCSK9 expression in hepatocytes — confirmed in cell culture models — represents a mechanism convergent with that of a major pharmaceutical drug class (PCSK9 inhibitors), though at a much lower potency.\n\nThe review also quantified the lipase inhibition effect: naringin reduced pancreatic lipase activity by approximately 30–40% in vitro at physiologically relevant concentrations, suggesting meaningful reduction in dietary fat hydrolysis and absorption. This effect would be additive to the hepatic lipid-lowering mechanisms.\n\nPopulation variability was an important theme: in individuals with obesity and diabetes, naringenin's lipid effects were less consistent than in lean or mildly hyperlipidemic models, possibly due to differences in gut microbiota composition (which affects naringenin bioactivation), hepatic insulin resistance (which alters PPARα responsiveness), and baseline LDL receptor expression.\n\nAnti-inflammatory and Neuroprotective Mechanisms …","deepTruncated":true,"references":[{"id":"1","title":"The Therapeutic Potential of Naringenin: A Review of Clinical Trials","authors":"Salehi B, Tsouh Fokou PV, Sharifi-Rad M, Zucca P, Pezzani R, Martins N, Sharifi-Rad J","year":2019,"journal":"Pharmaceuticals (Basel)","pmid":"30634637","url":"https://pubmed.ncbi.nlm.nih.gov/30634637/"},{"id":"2","title":"Naringenin and naringin in cardiovascular disease prevention: A preclinical review","authors":"Moghaddam RH, Samimi Z, Moradi SZ, Little PJ, Xu S, Farzaei MH","year":2020,"journal":"European Journal of Pharmacology","pmid":"32910944","url":"https://pubmed.ncbi.nlm.nih.gov/32910944/"},{"id":"3","title":"The Potential Role of Naringin and Naringenin as Nutraceuticals Against Metabolic Syndrome","authors":"Massaro L, Raguzzini A, Aiello P, Villaño Valencia D","year":2023,"journal":"Endocrine, Metabolic and Immune Disorders - Drug Targets","pmid":"36043734","url":"https://pubmed.ncbi.nlm.nih.gov/36043734/"},{"id":"4","title":"Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms","authors":"Yang Y, Trevethan M, Wang S, Zhao L","year":2022,"journal":"Journal of Nutritional Biochemistry","pmid":"35189328","url":"https://pubmed.ncbi.nlm.nih.gov/35189328/"},{"id":"5","title":"Naringenin: A Promising Immunomodulator for Anti-inflammatory, Neuroprotective and Anti-cancer Applications","authors":"Solanki S, Vig H, Khatri N, Singh BP, Khan MS, Devgun M, Wal P, Wal A","year":2025,"journal":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","pmid":"39076091","url":"https://pubmed.ncbi.nlm.nih.gov/39076091/"}],"wordCount":2044,"source":{"path":"src/content/topics/naringenin/anti-inflammatory-and-metabolic-health.md"},"citeAs":"“Does naringenin from grapefruit lower cholesterol and inflammation?.” What's Healthy and Why. https://whatshealthyandwhy.com/naringenin/anti-inflammatory-and-metabolic-health","notice":"General information backed by peer-reviewed research, not medical advice."}